Common light chain mouse

Patent metadata

Field	Value
Publication number	US-10143186-B2
Application number	US-201113022759-A
Country	US
Kind code	B2
Filing date	Feb 8, 2011
Priority date	Feb 8, 2010
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.

First claim

What is claimed is:

1. A mouse that is heterozygous or homozygous in its germline for:
(a) an insertion at an endogenous mouse κ immunoglobulin light chain variable region locus, wherein the insertion includes a rearranged Vκ/Jκ sequence encoding a κ immunoglobulin light chain variable domain, wherein the rearranged Vκ/Jκ sequence consists of:
a human Vκ1-39 gene segment joined to a human Jκ5 gene segment as set forth in nucleotides 2362 through 2686 of SEQ ID NO: 1, or
a human Vκ3-20 gene segment joined to a human Jκ1 gene segment as set forth in nucleotides 2373 through 2697 of SEQ ID NO: 1l;

wherein the rearranged Vκ/Jκ sequence is operably linked to the endogenous mouse κ constant region; and
(b) an insertion at an endogenous mouse immunoglobulin heavy chain variable region locus of a plurality of human immunoglobulin heavy chain variable region gene segments, wherein the human immunoglobulin heavy chain variable region gene segments are operably linked to an endogenous mouse immunoglobulin heavy chain constant region, and the human immunoglobulin heavy chain variable region gene segments are capable of rearranging and forming a rearranged human/mouse chimeric immunoglobulin heavy chain gene.

2. The mouse of claim 1 , wherein the mouse lacks an endogenous mouse κ immunoglobulin light chain variable region locus that is capable of rearranging and forming a mouse κ variable region sequence that encodes a mouse κ variable domain.

3. The mouse of claim 1 , further comprising a mouse κ intronic enhancer upstream of the endogenous mouse κ constant region.

4. The mouse of claim 1 , further comprising a mouse κ 3′ enhancer downstream of the endogenous mouse κ constant region.

5. The mouse of claim 1 , wherein the plurality of human immunoglobulin heavy chain variable region gene segments comprises at least one gene segment selected from the group consisting of V H 1-2, V H 1-8, V H 1-24, V H 2-5, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-20, V H 3-23, V H 3-30, V H 3-33, V H 3-43, V H 3-48, V H 4-31, V H 4-39, V H 4-59, V H 5-51 and V H 6-1.

6. The mouse of claim 1 , wherein the mouse comprises a population of B cells that together express a plurality of immunoglobulin heavy chains comprising human heavy chain variable domains expressed from rearranged human heavy chain variable region sequences comprising a V H 1-2, V H 1-8, V H 1-24, V H 2-5, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-20, V H 3-23, V H 3-30, V H 3-33, V H 3-43, V H 3-48, V H 4-31, V H 4-39, V H 4-59, V H 5-51, V H 6-1, or a somatically hypermutated variant thereof.

7. A method for selecting a human immunoglobulin heavy chain variable region sequence for making an antibody, comprising:
(a) immunizing a genetically modified mouse with an antigen of interest, wherein the mouse is heterozygous or homozygous in its germline for:
(i) an insertion at an endogenous mouse κ immunoglobulin light chain variable region locus, wherein the insertion includes a rearranged Vκ/Jκ sequence encoding a κ immunoglobulin light chain variable domain, wherein the rearranged Vκ/Jκ sequence consists of:
a human Vκ1-39 gene segment joined to a human Jκ5 gene segment as set forth in nucleotides 2362 through 2686 of SEQ ID NO: 1, or
a human Vκ3-20 gene segment joined to a human Jκ1 gene segment as set forth in nucleotides 2373 through 2697 of SEQ ID NO: 11;

wherein the rearranged human Vκ/Jκ sequence is operably linked to the endogenous mouse κ constant region; and
(ii) an insertion at an endogenous mouse immunoglobulin heavy chain variable region locus of a plurality of human immunoglobulin heavy chain variable region gene segments, wherein the human immunoglobulin heavy chain variable region gene segments are operably linked to an endogenous mouse immunoglobulin heavy chain constant region, and the human immunoglobulin heavy chain variable region segments are capable of rearranging and forming a rearranged human/mouse chimeric immunoglobulin heavy chain gene;

(b) allowing the mouse to develop an immune response to the antigen of interest; and
(c) identifying a lymphocyte of the mouse that expresses an antibody that specifically binds the antigen of interest, and obtaining a human immunoglobulin heavy chain variable region sequence that encodes a human immunoglobulin heavy chain variable domain of said antibody.

8. The method of claim 7 , wherein the mouse lacks an endogenous mouse κ immunoglobulin light chain variable region locus that is capable of rearranging and forming a mouse κ variable region sequence that encodes a mouse κ variable domain.

9. The method of claim 7 , wherein the mouse further comprises a mouse κ intronic enhancer upstream of the endogenous mouse κ constant region.

10. The method of claim 7 , wherein the mouse further comprises a mouse κ 3′ enhancer downstream of the endogenous mouse κ constant region.

11. The method of claim 7 , wherein the plurality of human immunoglobulin heavy chain variable region gene segments comprises at least one gene segment selected from the group consisting of VH1-2, VH1-8, VH1-24, VH2-5, VH3-7, VH3-9, VH3-11, VH3-13, VH3-15, VH3-20, VH3-23, VH3-30, VH3-33, VH3-43, VH3-48, VH4-31, VH4-39, VH4-59, VH5-51 and VH6-1.

12. The method of claim 7 , wherein the mouse comprises a population of B cells that together express a plurality of immunoglobulin heavy chains comprising human heavy chain variable domains expressed from rearranged human heavy chain variable region sequences comprising a V H 1-2, V H 1-8, V H 1-24, V H 2-5, V H 3-7, V H 3-9, V H 3-11, V H 3-13, V H 3-15, V H 3-20, V H 3-23, V H 3-30, V H 3-33, V H 3-43, V H 3-48, V H 4-31, V H 4-39, V H 4-59, V H 5-51, V H 6-1, or a somatically hypermutated variant thereof.

13. The method of claim 7 , wherein steps (a) through (c) are performed a first time for a first antigen of interest to generate a first human immunoglobulin heavy chain variable region sequence, and steps (a) through (c) are performed a second time for a second antigen of interest to generate a second human immunoglobulin heavy chain variable region sequence, and wherein the first human immunoglobulin heavy chain variable region sequence is expressed fused with a first human immunoglobulin heavy chain constant region to form a first human immunoglobulin heavy chain gene that encodes a first human immunoglobulin heavy chain, the second human immunoglobulin heavy chain variable region sequence is expressed fused with a second human immunoglobulin heavy chain constant region to form a second human immunoglobulin heavy chain gene that encodes a second human immunoglobulin heavy chain, and the first and the second human immunoglobulin heavy chains are expressed in the presence of a single human immunoglobulin light chain derived from the same rearranged Vκ/Jκ sequence as present in the mouse to generate a bispecific antibody.

14. A method of using a genetically modified mouse in making a human common light chain antibody, the mouse being genetically modified in that its germline:
(a) is homozygous or heterozygous for an insertion at an endogenous mouse κ immunoglobulin light chain variable region locus, wherein the insertion includes a rearranged Vκ/Jκ sequence encoding a κ immunoglobulin light chain variable domain, wherein the rearranged Vκ/Jκ sequence consists of:
a human Vκ1-39 gene segment joined to a human Jκ5 gene segment as set forth in nucleotides 2362 through 2686 of SEQ ID NO: 1, or
a human Vκ3-20 gene segment joined to a human Jκ1 gene segment as set forth in nucleotides 2373 through 2697 of SEQ ID NO: 11;

wherein the rearranged Vκ/Jκ sequence is operably linked to the endogenous mouse κ constant

Assignees

• Mcwhirter John
• Macdonald Lynn
• Stevens Sean
• Buckler David R
• Murphy Andrew J
• Regeneron Pharma

Inventors

• Mcwhirter John
• Macdonald Lynn
• Stevens Sean
• Buckler David R
• Murphy Andrew J

Classifications

• C07K16/22

  against growth factors {; against growth regulators} · CPC title

• C07K16/462

  Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another · CPC title

• C12N5/10

  Cells modified by introduction of foreign genetic material · CPC title

• C12N5/0606

  Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696) · CPC title

• A01K67/0276

  Knock-out vertebrates · CPC title